| | Identification | Back Directory |  | [Name] 
 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, compd. with methanesulfonate (1:1)
 |  | [CAS] 
 2134096-06-1
 |  | [Synonyms] 
 Almonertinib mesylate
 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, compd. with methanesulfonate (1:1)
 Almonertinib,EGFR tyrosine kinase inhibitor,Inhibitor,HER1,ErbB-1,third-generation,HS-10296,HS 10296,orally available,Almonertinib mesylate,inhibit,Epidermal growth factor receptor,irreversible,HS10296,non-small cell lung cancer,EGFR
 |  | [Molecular Formula] 
 C31H39N7O5S
 |  | [MOL File] 
 2134096-06-1.mol
 |  | [Molecular Weight] 
 621.76
 | 
 | Chemical Properties | Back Directory |  | [storage temp. ] 
 4°C, away from moisture
 |  | [solubility ] 
 DMSO : 31.25 mg/mL (50.26 mM; ultrasonic and warming and heat to 60°C)
 |  | [form ] 
 Solid
 |  | [color ] 
 Light yellow to yellow
 | 
 | Hazard Information | Back Directory |  | [Uses] 
 Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer[1][2].
 |  | [References] 
 [1] Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. J Thorac Oncol. 2020;S1556-0 DOI:10.1016/j.jtho.2020.09.001
 [2] Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76. DOI:10.3389/fmed.2016.00076
 | 
 | 
                    
                        
                            | Company Name: | CAREBIO  PHARMA  Gold |  
                            | Tel: | 18501057619 18501057619; |  
                            | Website: |  |  
                    
                        
                            | Company Name: | NewCan Biotech Limited |  
                            | Tel: | +86-0571-86912261 +86-15658003402 |  
                            | Website: | https://www.newcanbio.com/ |  |